<DOC>
	<DOCNO>NCT00037674</DOCNO>
	<brief_summary>This primary purpose study evaluate safety efficacy topiramate compare lithium placebo treatment acute manic mixed episodes patient Bipolar I Disorder .</brief_summary>
	<brief_title>A Study Safety Efficacy Topiramate Treatment Patients With Bipolar I Disorder</brief_title>
	<detailed_description>This randomize , double-blind , placebo- active-controlled study evaluate effectiveness two dose level topiramate ( 200 400 milligrams/day ) compare lithium placebo treatment acute manic mixed episodes patient Biplar I Disorder . The trial consist 3 phase : screening period ; double-blind treatment 12 week ; optional open-label period least 6 month . Efficacy assessment include change baseline Day 21 total Young Mania Rating Scale ( YMRS ) score . Also include efficacy assessment 12 week study Global Assessment Scale ( GAS ) , Montgomery-Ã…sberg Depression Rating Scale ( MADRS ) , Brief Psychiatric Rating Scale ( BPRS ) , Clinical Global Impressions ( CGI ) , health-related quality life measure specify time interval . Safety assessment include evaluation adverse event throughout study , rate withdrawal study due adverse event , vital sign ( blood pressure pulse ) througout study , well change clinical laboratory test ( hematology , chemistry , urinalysis ) , electrocardiogram ( ECGs ) , physical examination specify time . The study hypothesis change baseline Young Mania Rating Scale ( YMSR ) total score Day 21 significantly good topiramate group placebo group study drug well tolerated patient . Topiramate : oral tablet ( 50 milligram [ mg ] ) ; increase daily ( 50mg ) 3-times daily ; target total daily dose 200mg 400mg , maintain Week 12 . Lithium : oral capsule ( 300mg ) ; increase daily ( 300mg ) three-times daily ; target total daily dose 1500-1800 mg .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Diagnosis Bipolar I Disorder criterion Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) confirm Structured Clinical Interview DSMIV Axis I Disorders ( SCIDI ) At least one previous manic mixed episode Meeting minimum severity criterion ( Young Mania Rating Scale [ YMRS ] score &gt; =20 screen baseline visit ) current acute manic mixed episode Females must postmenopausal , surgically sterile , use adequate contraceptive measure , negative pregnancy test DSMIV diagnosis alcohol substance dependence ( exception nicotine caffeine dependence ) DSMIV Axis I diagnosis schizoaffective disorder impulse control disorder Experienced manic episode take antidepressant psychostimulant drug Known hypersensitivity topiramate previously participate topiramate study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Bipolar</keyword>
	<keyword>Mania</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Lithium</keyword>
</DOC>